Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A peptide sequence from mouse tissue factor inhibits human tissue factor dependent factor X activation

L Orning1, B E Arbo, P M Fischer

  • 1Nycomed Imaging AS, Oslo, Norway. lars.oerning@axisbio.no

Thrombosis Research
|November 7, 1998
PubMed
Summary

Synthetic peptides targeting factor X activation were developed. Murine-derived peptides showed potent inhibition of human tissue factor/factor VIIa, offering insights into coagulation pathways.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity.

Cell death & disease·2015
Same author

Coagulation factor XII protease domain crystal structure.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation.

European journal of clinical pharmacology·2012
Same author

The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin.

Journal of thrombosis and haemostasis : JTH·2011

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hemostasis and Thrombosis

Background:

  • The coagulation cascade involves complex interactions, including tissue factor (TF) and factor VIIa (FVIIa) initiating the extrinsic pathway by activating factor X (FX).
  • Synthetic peptides mimicking TF recognition sites are explored as potential modulators of coagulation.
  • Understanding species-specific differences in TF-FVIIa interactions is crucial for developing targeted anticoagulants.

Purpose of the Study:

  • To synthesize and evaluate synthetic peptides based on human, rabbit, and murine tissue factor recognition sites for their inhibitory activity.
  • To investigate the mechanism of inhibition of the most potent peptide, particularly the murine-derived peptide.
  • To explore structure-activity relationships by modifying the murine peptide sequence.

Related Experiment Videos

Main Methods:

  • Synthesis of three synthetic peptides corresponding to human, rabbit, and murine tissue factor recognition sequences.
  • Assay of peptide inhibition of human TF/FVIIa-catalyzed FX activation using dose-dependent inhibition studies.
  • Determination of IC50 values and mechanistic studies (competitive vs. noncompetitive inhibition) for the murine peptide.

Main Results:

  • All synthesized peptides demonstrated dose-dependent inhibition of human TF/FVIIa-mediated FX activation.
  • The murine peptide exhibited significant inhibitory activity (IC50 = 33 microM), surprisingly high given low sequence homology and functional differences with human TF.
  • The murine peptide acted noncompetitively towards FX but competitively towards TF, suggesting it binds to TF or the TF/FVIIa complex.
  • N-terminal truncation of the murine peptide did not alter activity or mechanism; substitution with glycine increased potency (IC50 = 17 microM).

Conclusions:

  • Synthetic peptides based on TF recognition sites can effectively inhibit TF/FVIIa-catalyzed FX activation.
  • The murine peptide is a potent inhibitor, highlighting its potential as a tool for studying coagulation or as a therapeutic lead.
  • Structural modifications, such as glycine substitution, can enhance the inhibitory potency and solubility of these peptides.